Abstract: A honokiol liposome transdermal gel includes by weight percentage: 1-40% honokiol liposome and 10-85% gel matrix. The honokiol liposome comprises phospholipid, honokiol, cholesterol, and polyethylene glycol or pegylated phospholipid, in a weight ratio of 2-10:1:0.3-0.6:0.1-0.3; and the gel matrix is poloxamer. The invention achieves an encapsulation efficiency of honokiol greater than 90%, the honokiol liposome transdermal gel has high transdermal efficiency, rapid and sustained absorption, and high stability, and shows good therapeutic effects for skin diseases.

Abstract: The present invention provides honokiol crystal forms A, B and C and amorphous form and a preparation method thereof, wherein the preparation method comprises dissolving honokiol in n-heptane and standing at room temperature overnight to obtain the separated crystal as honokiol crystal form A; heating the honokiol crystal form A and cooling to room temperature to obtain a solid as honokiol crystal form B; heating the honokiol crystal form A to the molten state and then standing at quenching temperature to obtain the separated crystal as honokiol crystal form C; and adding the honokiol crystal form A with an antisolvent in DMSO/H2O system, and thus obtaining the oily matter as honokiol amorphous form. The honokiol crystal forms A, B and C and the amorphous form of the present invention have the advantages of good solubility, good stability, low hygroscopicity, long-term storage and/or good reproducibility, and are suitable for drug development.

Abstract: The present invention provides honokiol crystal forms A, B and C and amorphous form and a preparation method thereof, wherein the preparation method comprises dissolving honokiol in n-heptane and standing at room temperature overnight to obtain the separated crystal as honokiol crystal form A; heating the honokiol crystal form A and cooling to room temperature to obtain a solid as honokiol crystal form B; heating the honokiol crystal form A to the molten state and then standing at quenching temperature to obtain the separated crystal as honokiol crystal form C; and adding the honokiol crystal form A with an antisolvent in DMSO/H2O system, and thus obtaining the oily matter as honokiol amorphous form. The honokiol crystal forms A, B and C and the amorphous form of the present invention have the advantages of good solubility, good stability, low hygroscopicity, long-term storage and/or good reproducibility, and are suitable for drug development.

Abstract: The invention involves the pharmaceutical use of honokiol, in particular the use of honokiol in inhibiting medulloblastoma, and it has been experimentally proved that honokiol can inhibit the proliferation and induce cell cycle arrest and apoptosis of medulloblastoma cells; promoting hair growth, and it has been experimentally proved that honokiol can promote hair growth and has no toxic and side effects on liver and kidney; and promoting white hair blackening, and it has been experimentally proved that honokiol can promote white hair blackening and has no toxic side effects on liver and kidney.

Abstract: The present disclosure discloses a desktop display stand base, comprising a fixing device connected to the desktop and a seat body respectively connected to the fixing device and the display stand, wherein a wireless charging device for mobile phones is provided on one side of the seat body, the side of which close to the user; the wireless charging device is hinged to the seat body and can be locked at any angle, and the hinge point is located on the side close to the user. In this way, the user can monitor the information on the mobile phone screen while the phone being charged.

Abstract: A display height-increasing platform with keyboard sterilization function, comprising a height-increasing platform body, a tablet top arranged on the upper end surface of the height-increasing platform body for supporting the display, a space formed in the lower portion of the height-increasing platform body for the placement of the keyboard; the space is provided with an ultraviolet disinfection unit, which is used for projecting the ultraviolet light onto the upper surface of the keyboard for sterilizing and disinfecting. With an internal ultraviolet disinfection unit in the platform, the keyboard can be disinfected and its cleanliness ensured as the breeding of bacteria avoided.

Abstract: The present disclosure discloses a desktop display stand base, comprising a fixing device connected to the desktop and a scat body respectively connected to the fixing device and the display stand, wherein a wireless charging device for mobile phones is provided on one side of the seat body, the side of which close to the user; the wireless charging device is hinged to the seat body and can be locked at any angle, and the hinge point is located on the side close to the user. In this way, the user can monitor the information on the mobile phone screen while the phone being charged.

Abstract: A compound represented by Formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims at acquiring, via a medicine design and a synthetic technology, a series of selective histone deacetylase inhibitors having good hypotype selectivity and favorable pharmacokinetic characteristics based on optimization of an enzyme surface recognition region and connection region of 4-arylamino quinazoline, thus reducing an effect on normal tissues or cells while improving an antineoplastic activity of the normal tissues or cells. In Formula I, the variables are as described herein.

Abstract: A compound represented by Formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims at acquiring, via a medicine design and a synthetic technology, a series of selective histone deacetylase inhibitors having good hypotype selectivity and favorable pharmacokinetic characteristics based on optimization of an enzyme surface recognition region and connection region of 4-arylamino quinazoline, thus reducing an effect on normal tissues or cells while improving an antineoplastic activity of the normal tissues or cells.